Abstract:Abstract Background The CRISPR-Cas12a (formerly Cpf1) system is a versatile gene-editing tool with properties distinct from the broadly used Cas9 system. Features such as recognition of T-rich protospacer-adjacent motif (PAM) and generation of sticky breaks, as well as amenability for multiplex editing in a single crRNA and lower off-target nuclease activity, broaden the targeting scope of available tools and enable more accurate genome editing. However, the widespread use of the nuclease for gene editing, especially in clinical applications, is hindered by insufficient activity and specificity despite previous efforts to improve the system. Currently reported Cas12a variants achieve high activity with a compromise of specificity. Here, we used structure-guided protein engineering to improve both editing efficiency and targeting accuracy of Acidaminococcus sp. Cas12a ( As Cas12a) and Lachnospiraceae bacterium Cas12a ( Lb Cas12a). Results We created new As Cas12a variant termed “ As Cas12a-Plus” with increased activity (1.5~2.0-fold improvement) and specificity (reducing off-targets from 29 to 23 and specificity index increased from 92% to 94% with 33 sgRNAs), and this property was retained in multiplex editing and transcriptional activation. When used to disrupt the oncogenic BRAF V600E mutant, As Cas12a-Plus showed less off-target activity while maintaining comparable editing efficiency and BRAF V600E cancer cell killing. By introducing the corresponding substitutions into Lb Cas12a, we also generated Lb Cas12a-Plus (activity improved ~1.1-fold and off-targets decreased from 20 to 12 while specificity index increased from 78% to 89% with 15 sgRNAs), suggesting this strategy may be generally applicable across Cas12a orthologs. We compared Cas12a-Plus, other variants described in this study, and the reported enCas12a-HF, enCas12a, and Cas12a-ultra, and found that Cas12a-Plus outperformed other variants with a good balance for enhanced activity and improved specificity. Conclusions Our discoveries provide alternative As Cas12a and Lb Cas12a variants with high specificity and activity, which expand the gene-editing toolbox and can be more suitable for clinical applications.

Discovery and engineering of ChCas12b for precise genome editing

SgRNA Engineering for Improved Genome Editing and Expanded Functional Assays.

Engineering of a high-fidelity Cas12a nuclease variant capable of allele-specific editing

Discovery and Engineering of a New BvCas12a Nuclease for Mammalian Genome Editing and Nucleic Acid Detection

Expanding the CRISPR toolbox by engineering Cas12a orthologs of metagenomic discovery

A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing

Genome editing with natural and engineered CjCas9 orthologs

High-Throughput Profiling of Cas12a Orthologues and Engineered Variants for Enhanced Genome Editing Activity

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Lb2Cas12a and Its Engineered Variants Mediate Genome Editing in Human Cells.

Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity

Characterization of NiCas12b for in Vivo Genome Editing.

Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing

An engineered Cas12i nuclease that is an efficient genome editing tool in animals and plants

Multiplexed base editing through Cas12a variant-mediated cytosine and adenine base editors

Improved genome editing by an engineered CRISPR-Cas12a

Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

Improving the efficiency of CRISPR-Cas12a-based genome editing with site-specific covalent Cas12a-crRNA conjugates

Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening

Structure and genome editing activity of the novel CRISPR-Cas12o1 effector